Chronic oral or intraarticular administration of docosahexaenoic acid reduces nociception and knee edema and improves functional outcomes in a mouse model of Complete Freund's Adjuvant-induced knee arthritis

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Torres Guzman, Ana M ^a   Morado Urbina, Carlos E ^a   Alvarado Vazquez, Perla A ^a   Acosta Gonzalez, Rosa I ^a   Chávez Piña, Aracely E ^b   Montiel Ruiz, Rosa M ^a   Jimenez Andrade, Juan M ^a  

^a UNIVERSIDAD AUTÓNOMA DE TAMAULIPAS   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; FREUND ADJUVANT; NALOXONE; OPIATE; DOCOSAHEXAENOIC ACIDS; FREUND'S ADJUVANT;

ADULT; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EDEMA; EXPLORATORY BEHAVIOR; KNEE ARTHRITIS; KNEE EDEMA; KNEE PAIN; LIMB; LONG TERM CARE; MALE; MOUSE; NOCICEPTION; NONHUMAN; OPEN FIELD TEST; REARING; TREATMENT DURATION; TREATMENT OUTCOME; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DRUG EFFECTS; KNEE JOINT; MICE; MICE, INBRED ICR; PAIN; PATHOLOGY; ACUTE DRUG ADMINISTRATION; ADJUVANT ARTHRITIS; ANTINOCICEPTION; CHRONIC DRUG ADMINISTRATION; DOSE RESPONSE; DRUG DOSE COMPARISON; FUNCTIONAL STATUS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DOCOSAHEXAENOIC ACIDS; EDEMA; FREUND'S ADJUVANT; KNEE JOINT; MALE; MICE; MICE, INBRED ICR; PAIN;

EID: 84897992018     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4502     Document Type: Article

References (65)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010, 376:1094-1108. 10.1016/S0140-6736(10)60826-4, 20870100.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361. 10.1038/nature01661, 12748655.
3. Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 2002, 16:707-722. 10.1053/berh.2002.0257, 12473269.
4. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003, 81:646-656. 2572542, 14710506.
5. Lubeck DP. The costs of musculoskeletal disease: health needs assessment and health economics. Best Pract Res Clin Rheumatol 2003, 17:529-539.
6. Brooks PM. The burden of musculoskeletal disease-a global perspective. Clin Rheumatol 2006, 25:778-781. 10.1007/s10067-006-0240-3, 16609823.
7. Cisternas MG, Murphy LB, Yelin EH, Foreman AJ, Pasta DJ, Helmick CG. Trends in medical care expenditures of US adults with arthritis and other rheumatic conditions 1997 to 2005. J Rheumatol 2009, 36:2531-2538. 10.3899/jrheum.081068, 3721311, 19797505.
8. van Laar M, Pergolizzi JV, Mellinghoff HU, Merchante IM, Nalamachu S, O'Brien J, Perrot S, Raffa RB. Pain treatment in arthritis-related pain: beyond NSAIDs. Open Rheumatol J 2012, 6:320-330. 10.2174/1874312901206010320, 3527878, 23264838.
9. Tragulpiankit P, Chulavatnatol S, Rerkpattanapipat T, Janwityanujit S, Somjarit S, Sirikhedgon U. Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients. Int J Rheum Dis 2012, 15:315-321. 10.1111/j.1756-185X.2012.01716.x, 22709494.
10. Ong CK, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 2007, 5:19-34. 10.3121/cmr.2007.698, 1855338, 17456832.
11. Choy EH, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 2005, 44:1414-1421. 10.1093/rheumatology/kei031, 16030080.
12. Calder PC. Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids 2006, 75:197-202. 10.1016/j.plefa.2006.05.012, 16828270.
13. Ruggiero C, Lattanzio F, Lauretani F, Gasperini B, Andres-Lacueva C, Cherubini A. Ω-3 polyunsaturated fatty acids and immune-mediated diseases: inflammatory bowel disease and rheumatoid arthritis. Curr Pharm Des 2009, 15:4135-4148. 10.2174/138161209789909746, 20041815.
14. Miles EA, Calder PC. Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. Br J Nutr 2012, 107:S171-S184. 10.1017/S0007114512001560, 22591891.
15. Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of ω-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 2007, 129:210-223. 10.1016/j.pain.2007.01.020, 17335973.
16. Park Y, Lee A, Shim SC, Lee JH, Choe JY, Ahn H, Choi CB, Sung YK, Bae SC. Effect of ω-3 polyunsaturated fatty acid supplementation in patients with rheumatoid arthritis: a 16-week randomized, double-blind, placebo-controlled, parallel-design multicenter study in Korea. J Nutr Biochem 2013, 24:1367-1372. 10.1016/j.jnutbio.2012.11.004, 23333088.
17. Yuan J, Akiyama M, Nakahama K, Sato T, Uematsu H, Morita I. The effects of polyunsaturated fatty acids and their metabolites on osteoclastogenesis in vitro. Prostaglandins Other Lipid Mediat 2010, 92:85-90. 10.1016/j.prostaglandins.2010.04.001, 20394833.
18. Rahman MM, Bhattacharya A, Fernandes G. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. J Cell Physiol 2008, 214:201-209. 10.1002/jcp.21188, 17929247.
19. Raederstorff D, Pantze M, Bachmann H, Moser U. Anti-inflammatory properties of docosahexaenoic and eicosapentaenoic acids in phorbol-ester-induced mouse ear inflammation. Int Arch Allergy Immunol 1996, 111:284-290. 10.1159/000237379, 8917124.
20. Wagstaff S, Smith OV, Wood PH. Verbal pain descriptors used by patients with arthritis. Ann Rheum Dis 1985, 44:262-265. 10.1136/ard.44.4.262, 1001623, 3985692.
21. Papageorgiou AC, Badley EM. The quality of pain in arthritis: the words patients use to describe overall pain and pain in individual joints at rest and on movement. J Rheumatol 1989, 16:106-112.
22. Schaible HG, Ebersberger A, Von Banchet GS. Mechanisms of pain in arthritis. Ann N Y Acad Sci 2002, 966:343-354. 10.1111/j.1749-6632.2002.tb04234.x, 12114291.
23. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984, 27:968-975. 10.1002/art.1780270902, 6236824.
24. Nagae M, Hiraga T, Wakabayashi H, Wang L, Iwata K, Yoneda T. Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone 2006, 39:1107-1115. 10.1016/j.bone.2006.04.033, 16769263.
25. Oliver E, McGillicuddy FC, Harford KA, Reynolds CM, Phillips CM, Ferguson JF, Roche HM. Docosahexaenoic acid attenuates macrophage-induced inflammation and improves insulin sensitivity in adipocytes-specific differential effects between LC ω-3 PUFA. J Nutr Biochem 2012, 23:1192-1200. 10.1016/j.jnutbio.2011.06.014, 22137266.
26. Olson MV, Liu YC, Dangi B. Docosahexaenoic acid reduces inflammation and joint destruction in mice with collagen-induced arthritis. Inflamm Res 2013, 62:1003-1013. 10.1007/s00011-013-0658-4, 24008816.
27. Okamoto K, Takayanagi H. Osteoclasts in arthritis and Th17 cell development. Int Immunopharmacol 2011, 11:543-548. 10.1016/j.intimp.2010.11.010, 21081190.
28. Allen KD, Adams SB, Setton LA. Evaluating intra-articular drug delivery for the treatment of osteoarthritis in a rat model. Tissue Eng Part B Rev 2010, 16:81-92. 2817653, 19943805.
29. Chevalier X. Intraarticular treatments for osteoarthritis: new perspectives. Curr Drug Targets 2010, 11:546-560. 10.2174/138945010791011866, 20199394.
30. Edwards SH. Intra-articular drug delivery: the challenge to extend drug residence time within the joint. Vet J 2011, 190:15-21. 10.1016/j.tvjl.2010.09.019, 20947396.
31. Gerwin N, Hops C, Lucke A. Intraarticular drug delivery in osteoarthritis. Adv Drug Deliv Rev 2006, 58:226-242. 10.1016/j.addr.2006.01.018, 16574267.
32. Nakamoto K, Nishinaka T, Mankura M, Fujita-Hamabe W, Tokuyama S. Antinociceptive effects of docosahexaenoic acid against various pain stimuli in mice. Biol Pharm Bull 2010, 33:1070-1072. 10.1248/bpb.33.1070, 20522981.
33. Nakamoto K, Nishinaka T, Matsumoto K, Kasuya F, Mankura M, Koyama Y, Tokuyama S. Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system. Brain Res 2012, 1432:74-83.
34. Lu Y, Zhao LX, Cao DL, Gao YJ. Spinal injection of docosahexaenoic acid attenuates carrageenan-induced inflammatory pain through inhibition of microglia-mediated neuroinflammation in the spinal cord. Neuroscience 2013, 241:22-31.
35. Park CK, Xu ZZ, Liu T, Lü N, Serhan CN, Ji RR. Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. J Neurosci 2011, 31:18433-18438. 10.1523/JNEUROSCI.4192-11.2011, 3242808, 22171045.
36. Matta JA, Miyares RL, Ahern GP. TRPV1 is a novel target for ω-3 polyunsaturated fatty acids. J Physiol 2007, 578:397-411. 2075157, 17038422.
37. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110. 10.1016/0304-3959(83)90201-4, 6877845.
38. Gauldie SD, McQueen DS, Clarke CJ, Chessell IP. A robust model of adjuvant-induced chronic unilateral arthritis in two mouse strains. J Neurosci Methods 2004, 139:281-291. 10.1016/j.jneumeth.2004.05.003, 15488242.
39. Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Coughlin KA, Kaczmarska MJ, Castaneda-Corral G, Bloom AP, Kuskowski MA, Mantyh PW. Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum 2012, 64:2223-2232. 10.1002/art.34385, 3386465, 22246649.
40. Jimenez-Andrade JM, Mantyh PW. Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice. Arthritis Res Ther 2012, 14:R101. 10.1186/ar3826, 3446478, 22548760.
41. Jimenez-Andrade JM, Mantyh WG, Bloom AP, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW. The effect of aging on the density of the sensory nerve fiber innervation of bone and acute skeletal pain. Neurobiol Aging 2012, 33:921-932. 10.1016/j.neurobiolaging.2010.08.008, 3113456, 20947214.
42. Rojkovich B, Gibson T. Day and night pain measurement in rheumatoid arthritis. Ann Rheum Dis 1998, 57:434-436. 10.1136/ard.57.7.434, 1752669, 9797572.
43. Koewler NJ, Freeman KT, Buus RJ, Herrera MB, Jimenez-Andrade JM, Ghilardi JR, Peters CM, Sullivan LJ, Kuskowski MA, Lewis JL, Mantyh PW. Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6 J mouse femur. J Bone Miner Res 2007, 22:1732-1742. 10.1359/jbmr.070711, 17638576.
44. Tadaiesky MT, Andreatini R, Vital MABF. Different effects of 7-nitroindazole in reserpine-induced hypolocomotion in two strains of mice. Eur J Pharmacol 2006, 535:199-207. 10.1016/j.ejphar.2006.02.004, 16546164.
45. Rodrigues MRA, Kanazawa LKS, Neves TL MD, da Silva CF, Horst H, Pizzolatti MG, Santos ARS, Baggio CH, de Paula Werner MF. Antinociceptive and anti-inflammatory potential of extract and isolated compounds from the leaves of Salvia officinalis in mice. J Ethnopharmacol 2012, 139:519-526. 10.1016/j.jep.2011.11.042, 22154965.
46. Shimura T, Miura T, Usami M, Ishihara E, Tanigawa K, Ishida H, Seino Y. Docosahexaenoic acid (DHA) improved glucose and lipid metabolism in KK-Ay mice with genetic non-insulin-dependent diabetes mellitus (NIDDM). Biol Pharm Bull 1997, 20:507-510. 10.1248/bpb.20.507, 9178930.
47. Schmitt D, Tran N, Peach J, Bauter M, Marone P. Toxicologic evaluation of DHA-rich algal oil: genotoxicity, acute and subchronic toxicity in rats. Food Chem Toxicol 2012, 50:3567-3576. 10.1016/j.fct.2012.07.054, 22898615.
48. Lien EL. Toxicology and safety of DHA. Prostaglandins Leukot Essent Fatty Acids 2009, 81:125-132. 10.1016/j.plefa.2009.05.004, 19501496.
49. Sevcik MA, Jonas BM, Lindsay TH, Halvorson KG, Ghilardi JR, Kuskowski MA, Mukherjee P, Maggio JE, Mantyh PW. Endogenous opioids inhibit early-stage pancreatic pain in a mouse model of pancreatic cancer. Gastroenterology 2006, 131:900-910. 10.1053/j.gastro.2006.06.021, 2100397, 16952558.
50. Raehal KM, Lowery JJ, Bhamidipati CM, Paolino RM, Blair JR, Wang D, Sadée W, Bilsky EJ. In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther 2005, 313:1150-1162. 10.1124/jpet.104.082966, 15716384.
51. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet 2005, 365:965-973. 10.1016/S0140-6736(05)71086-2, 15766999.
52. Izumi M, Ikeuchi M, Ji Q, Tani T. Local ASIC3 modulates pain and disease progression in a rat model of osteoarthritis. J Biomed Sci 2012, 19:77. 10.1186/1423-0127-19-77, 3520115, 22909215.
53. Dawczynski C, Schubert R, Hein G, Müller A, Eidner T, Vogelsang H, Basu S, Jahreis G. Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis. Br J Nutr 2009, 101:1517-1526. 10.1017/S0007114508076216, 19245735.
54. Pisetsky DS, Ward MM. Advances in the treatment of inflammatory arthritis. Best Pract Res Clin Rheumatol 2012, 26:251-261. 10.1016/j.berh.2012.03.001, 3461328, 22794097.
55. Hoes JN, Jacobs JWG, Buttgereit F, Bijlsma JWJ. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010, 6:693-702. 10.1038/nrrheum.2010.179, 21119718.
56. Konai MS, Vilar Furtado RN, dos Santos MF, Natour J. Monoarticular corticosteroid injection versus systemic administration in the treatment of rheumatoid arthritis patients: a randomized double-blind controlled study. Clin Exp Rheumatol 2009, 27:214-221.
57. Shemesh S, Heller S, Salai M, Velkes S. Septic arthritis of the knee following intraarticular injections in elderly patients: report of six patients. Isr Med Assoc J 2011, 13:757-760.
58. Nakamoto K, Nishinaka T, Ambo A, Mankura M, Kasuya F, Tokuyama S. Possible involvement of β-endorphin in docosahexaenoic acid-induced antinociception. Eur J Pharmacol 2011, 666:100-104. 10.1016/j.ejphar.2011.05.047, 21658380.
59. Elbeialy A, Elbarbary M, Kamel M. Peripheral β-endorphin in rheumatoid arthritis: a correlation with the disease activity. Scand J Rheumatol 1997, 26:88-91. 10.3109/03009749709115824, 9137321.
60. Pineda-Peña EA, Jiménez-Andrade JM, Castañeda-Hernández G, Chávez-Piña AE. Docosahexaenoic acid, an ω-3 polyunsaturated acid protects against indomethacin-induced gastric injury. Eur J Pharmacol 2012, 697:139-143. 10.1016/j.ejphar.2012.09.049, 23063544.
61. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006, 83:1505S-1519S.
62. Lee TH, Mencia-Huerta JM, Shih C, Corey EJ, Lewis RA, Austen KF. Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest 1984, 74:1922-1933. 10.1172/JCI111612, 425378, 6096400.
63. Li X, Yu Y, Funk CD. Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4). FASEB J 2013, 27:4987-4997. 10.1096/fj.13-235333, 24005906.
64. Serhan CN. Novel chemical mediators in the resolution of inflammation: resolvins and protectins. Anesthesiol Clin 2006, 24:341-364. 10.1016/j.atc.2006.01.003, 16927933.
65. Hong MP, Kim HI, Shin YK, Lee CS, Park M, Song JH. Effects of free fatty acids on sodium currents in rat dorsal root ganglion neurons. Brain Res 2004, 1008:81-91. 10.1016/j.brainres.2004.02.033, 15081385.